The Pharma Data

MARCH 18, 2021

Earlier today, the MHRA announced their review of the small number of thromboembolic events in over 11 million people who received COVID-19 Vaccine AstraZeneca in the UK. After vaccination, the surface spike protein is produced, priming the immune system to attack the SARS-CoV-2 virus if it later infects the body.

Vaccine 52

Vaccine Virus Regulations Production 52

The Pharma Data

MARCH 8, 2021

The companies today reported findings on one secondary objective from the Phase 2a study, showing a reduction in time (days) to negativity of infectious virus isolation in nasopharyngeal swabs from participants with symptomatic SARS-CoV-2 infection, as determined by isolation in Vero cell line culture. About Molnupiravir.

Trials 69

Trials Virus RNA Research Laboratories 69

The Pharma Data

OCTOBER 28, 2020

In the overall patient group with detectable virus at baseline, the average daily reduction in viral load through day 7 was a 0.36 Serious adverse events were numerically more frequent with placebo than REGN-COV2 treatment (0.8% There was a 1.08 REGN-COV2 was well tolerated in the trial. high dose, 1.6% low dose; 2.3%

Virus 40

Virus Trials Clinical Trials Production 40

The Pharma Data

MARCH 14, 2021

Following a recent concern raised around thrombotic events, AstraZeneca would like to offer its reassurance on the safety of its COVID-19 vaccine based on clear scientific evidence. Furthermore, in clinical trials, even though the number of thrombotic events was small, these were lower in the vaccinated group.

Vaccine 52

Vaccine Virus Licensing Licensing 52

Drug Target Review

SEPTEMBER 8, 2023

However, recent insights indicate that it also operates beyond the nucleus, orchestrating initial events at the cell surface that trigger the activation of T cells. There are hundreds to thousands of dynamic phosphorylation events that occur during the first hour or so of T cell stimulation,” says Myers.

Regulations 98

Regulations Research DNA Immune Response 98

The Pharma Data

JULY 28, 2021

Incidence of very rare thromboembolic events was far lower than in people diagnosed with COVID-19 infection. 1 Follow-up time was not sufficient to report rates after two doses of Vaxzevria , though other studies have shown rates of rare blood clotting events to be lower after a second dose.

Vaccine 52

Vaccine Virus Science Disease 52

The Pharma Data

SEPTEMBER 5, 2021

Member States will be provided with regular delivery schedules, and capped rebates will apply in the event of any delayed doses. Early diagnosis allows appropriate treatment of these events 4,5 and there is no elevation of the risk of TTS at the second dose, compared to the rates expected in the general population.

Vaccine 52

Vaccine Virus Clinical Trials Trials 52

FDA Law Blog: Drug Discovery

DECEMBER 7, 2022

This was despite the 6-month data also demonstrating clinical benefits in reduction of bleeding events and declines in the use of FIX replacement therapy. At the same time, it is understandably important to be able to measure and characterize a treatment’s effect over time.

Therapies 119

Therapies FDA FDA Approval Treatment 119

Drug Target Review

DECEMBER 5, 2024

Challenges of viral capsids in gene therapy efficiency A widely used production method of rAAV vectors requires co-transfection of host cell lines with three plasmids, including one carrying the transgene of interest, one carrying the capsid and replication sequences, and a helper virus to circumvent the inability of rAAV to self-amplify.

Therapies 52

Therapies Virus DNA Compliance 52

The Pharma Data

JANUARY 13, 2021

The researchers found that the most frequent adverse events were fatigue, headache, myalgia, and injection-site pain after administration of the first vaccine dose in 805 participants in cohorts 1 and 3 and after the second dose in cohort 1. Fever was the most frequent systemic adverse event.

Vaccine 52

Vaccine Virus Trials Research 52

The Pharma Data

NOVEMBER 10, 2020

S, following a pause last month to investigate an adverse event. S is derived from a common cold virus that is modified to carry a gene from the SARS-CoV-2 virus which causes COVID-19, prompting the immune system to develop resistance to the virus. Source link.

Vaccine 40

Vaccine Trials Clinical Trials Virus 40

The Pharma Data

JANUARY 8, 2021

While speaking at a virtual event hosted by Oddo BHF, a financial service group, Bancel said the “nightmare scenario” that the vaccine will not work is now in the past. FRIDAY, Jan. 8, 2021 — Moderna CEO Stéphane Bancel said the company’s COVID-19 vaccine may prevent infection for years, CBS News reported Thursday.

Vaccine 52

Vaccine Virus Disease 52

The Pharma Data

DECEMBER 3, 2020

No serious adverse events related to the vaccine candidates studied were reported. The majority of adverse events were mild and transient. Similar to other enveloped RNA viruses such as HIV, RSV and Influenza, SARS-CoV-2 is also an RNA virus that has a trimeric spike (S) protein on its viral envelope.

Vaccine 52

Vaccine Immune Response Virus RNA 52

The Pharma Data

SEPTEMBER 3, 2020

S, prevented severe clinical disease in Syrian golden hamsters, upon challenge with SARS-CoV-2, the virus that causes COVID-19 in people. Four weeks later, the animals were exposed to a high dose of SARS-CoV-2 virus. These statements are based on current expectations of future events. Source link.

Vaccine 52

Vaccine Disease Immune Response Pharmaceutical Companies 52

The Pharma Data

JANUARY 31, 2021

No serious adverse events related to the vaccine candidates studied were reported. Similar to other enveloped RNA viruses such as HIV, RSV and Influenza, SARS-CoV-2 is also an RNA virus that has a trimeric spike (S) protein on its viral envelope. The candidate vaccines were given in two doses, three weeks apart.

Clinical Trials 52

Clinical Trials Vaccine Trials Virus 52

The Pharma Data

NOVEMBER 22, 2020

There were no serious adverse safety events. They use mRNA that codes for the spike protein in the SARS-CoV-2 virus, which is embedded in a nanolipid particle—basically a minuscule fat molecule. When injected into the body, cells churn out the spike protein, which causes the body’s immune system to recognize the virus.

Vaccine 52

Vaccine Virus Trials Regulations 52

The Pharma Data

OCTOBER 15, 2020

15, 2020 — A single pick-up hockey game in Tampa Bay in June wound up becoming a COVID-19 superspreader event, with one player infecting as many as 15 other people on the ice, Florida public health officials report. THURSDAY, Oct. The other two sick people were not tested for COVID.

Virus 52

Virus Disease 52

Nvidia Developer: Drug Discovery

APRIL 20, 2020

To help make the process for scientists more accessible, we’re spotlighting a few of the GPU-accelerated applications that developers can use right now in the fight against this virus. For example, events such as folding and docking can take micro- and milliseconds to occur.

Small Molecule 52

Small Molecule Virus Laboratories Science 52

The Pharma Data

OCTOBER 26, 2020

Hasan Jafri , Chief Medical Officer of Aridis Pharmaceuticals, will be a speaker on a panel entitled “Direct Antivirals and Other Agents Against SARS-CoV2 Virus.” ” Panel: Direct Antivirals and Other Agents Against SARS-CoV2 Virus Date: Wednesday, October 28, 2020 Time: 10:30AM- 11:50AM ET.

Pharmaceuticals 52

Pharmaceuticals Virus Hospitals Clinical Trials 52

The Pharma Data

SEPTEMBER 7, 2020

The event at Burnside Working Men’s Club (WMC), in Fencehouses on the border of Sunderland and Durham, took place on 30 August. “This is essential if we are to stop the spread of the virus in this community as quickly as possible.” The outbreak is linked to a charity match at Burnside Working Men’s Club.

Virus 52

Virus 52

The Pharma Data

NOVEMBER 9, 2020

Data from the event-driven trial could support global authorization and approval, including in the U.S. Depending on the overall COVID-19 attack rate, interim data in the UK trial, which is also event-driven, are expected as soon as early first quarter 2021. and globally.”. About NVX-CoV2373.

Vaccine 52

Vaccine FDA Clinical Trials Immune Response 52

The Pharma Data

SEPTEMBER 30, 2021

That’s how easy it’s for SARS-CoV-2, the virus that causes COVID-19, to enter your nose. Anderson Professor of Chemical and Biomolecular Engineering, and his colleagues, are reporting in iScience the event of an intranasal subunit vaccine that gives durable local immunity against inhaled pathogens. Breathe in, exhale.

Vaccine 52

Vaccine Disease Immune Response Virus 52

The Pharma Data

SEPTEMBER 9, 2020

The law also allows for 30 people to gather for a community event or a wedding, but police have had no powers to stop general gatherings of up to 30 and they believe the rules have frequently been abused. . From Monday, this will change to reduce the maximum to six people both inside and outside.

Virus 52

Virus 52

The Pharma Data

DECEMBER 28, 2020

We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events. . HOUSTON , Dec. 29, 2020 /PRNewswire/ — Moleculin Biotech , Inc., Moleculin Biotech, Inc.

FDA 52

FDA Clinical Trials Drugs Pharmaceutical Companies 52

The Pharma Data

DECEMBER 17, 2020

In the initial 275 patients, rates of adverse events (AEs) were similar among groups. The event began within 1 hour of completion of the infusion, and required treatment including epinephrine. The event resolved. All events resolved. Serious AEs occurred in 2 placebo patients, 1 low-dose patient and 0 high-dose patients.

Hospitals 52

Hospitals Production Clinical Trials Virus 52

The Pharma Data

DECEMBER 11, 2020

11, 2020 — More than 15 million Americans have been infected by the COVID-19 virus, and many may be questioning whether they need to receive one of the two coronavirus vaccines now on the verge of approval from U.S. FRIDAY, Dec. regulators. Short answer: Yes.

Vaccine 52

Vaccine Immune Response Virus Trials 52

The Pharma Data

NOVEMBER 17, 2021

It uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein. Available at: [link] [Accessed August 2021] 6. Available at SSRN: [link] [Accessed July 2021] 7.

Vaccine 52

Vaccine Clinical Trials Virus Licensing 52

The Pharma Data

JANUARY 29, 2021

It uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein.

Vaccine 52

Vaccine Clinical Trials Virus Trials 52

The Pharma Data

JANUARY 29, 2021

It uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein.

Vaccine 52

Vaccine Clinical Trials Virus Trials 52

The Pharma Data

JANUARY 31, 2021

” Dr. Richard Hatchett , Chief Executive Officer of CEPI, commented: “To end the acute phase of this pandemic, and to control the virus in the longer term, the world needs multiple safe and effective vaccines which can be deployed in a range of populations and countries. Securities and Exchange Commission.

Vaccine 52

Vaccine Trials Virus RNA 52

The Pharma Data

NOVEMBER 10, 2020

The Quebec City-based vaccine developer said that an interim analysis from the phase 1 study also showed no severe adverse events, and generally mild-to-moderate and brief reactogenicity events. Based on the promising phase 1 data, the company plans to proceed with a phase 2/3 clinical trial. “We Martin Berman-Gorvine.

Immune Response 40

Immune Response Vaccine Clinical Trials Virus 40

The Pharma Data

OCTOBER 30, 2020

About REGN-COV2 REGN-COV2 is a combination of two monoclonal antibodies (REGN10933 and REGN10987) and was designed specifically to block infectivity of SARS-CoV-2, the virus that causes COVID-19.

Hospitals 52

Hospitals Virus Production Clinical Trials 52

The Pharma Data

NOVEMBER 23, 2020

No serious safety events related to the vaccine have been confirmed. Trial participants to date are aged 18 years or over, who are healthy or have medically stable chronic diseases and are at increased risk for being exposed to the SARS-CoV-2 virus. AZD1222 was well tolerated across both dosing regimens. AstraZeneca.

Vaccine 52

Vaccine Virus Trials Clinical Trials 52

The Pharma Data

DECEMBER 30, 2020

It uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein. The overall reported rates of serious adverse events were 0.7% in the vaccine group and 0.8%

Vaccine 52

Vaccine Clinical Trials Virus Trials 52

The Pharma Data

SEPTEMBER 25, 2020

Based on these findings, the single dose of the Janssen COVID-19 vaccine candidate of 5×10 10 virus particles (vp) has been selected for further evaluation in the Phase 3 ENSEMBLE clinical trial. These statements are based on current expectations of future events. Source link.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

DECEMBER 28, 2020

BetterLife is refining and developing drug candidates from a broad set of complementary interferon-based technologies which have the potential to engage the immune system to fight virus infections, such as the coronavirus disease (COVID-19) and human papillomavirus (HPV), and/or to directly inhibit tumours to treat specific types of cancer.

Licensing 52

Licensing Licensing Compliance Virus 52

The Pharma Data

SEPTEMBER 5, 2021

The analyses compared specific health events among all COVID-19 mRNA-vaccinated people during the first 3 weeks after inoculation with health events among similar types of patients during the 3 to 6 weeks after mRNA vaccination. Surveillance for Adverse Events After COVID-19 mRNA Vaccination. million for the second dose. .

Vaccine 52

Vaccine Clinical Trials Research Virus 52